S&P 500   3,236.92 (-2.37%)
DOW   26,763.13 (-1.92%)
QQQ   264.16 (-3.05%)
AAPL   107.12 (-4.19%)
MSFT   200.59 (-3.29%)
FB   249.02 (-2.25%)
GOOGL   1,409.39 (-3.45%)
AMZN   2,999.86 (-4.13%)
NVDA   484.95 (-4.07%)
TSLA   380.36 (-10.34%)
BABA   272.95 (-0.85%)
CGC   14.60 (-8.98%)
GE   6.11 (-2.24%)
MU   49.85 (+0.30%)
AMD   74.73 (-3.82%)
T   27.87 (-2.24%)
F   6.64 (-2.06%)
ACB   5.17 (-29.37%)
GILD   63.09 (-0.49%)
NFLX   470.61 (-4.19%)
DIS   123.28 (-3.09%)
BAC   23.26 (-2.84%)
BA   151.18 (-3.58%)
S&P 500   3,236.92 (-2.37%)
DOW   26,763.13 (-1.92%)
QQQ   264.16 (-3.05%)
AAPL   107.12 (-4.19%)
MSFT   200.59 (-3.29%)
FB   249.02 (-2.25%)
GOOGL   1,409.39 (-3.45%)
AMZN   2,999.86 (-4.13%)
NVDA   484.95 (-4.07%)
TSLA   380.36 (-10.34%)
BABA   272.95 (-0.85%)
CGC   14.60 (-8.98%)
GE   6.11 (-2.24%)
MU   49.85 (+0.30%)
AMD   74.73 (-3.82%)
T   27.87 (-2.24%)
F   6.64 (-2.06%)
ACB   5.17 (-29.37%)
GILD   63.09 (-0.49%)
NFLX   470.61 (-4.19%)
DIS   123.28 (-3.09%)
BAC   23.26 (-2.84%)
BA   151.18 (-3.58%)
S&P 500   3,236.92 (-2.37%)
DOW   26,763.13 (-1.92%)
QQQ   264.16 (-3.05%)
AAPL   107.12 (-4.19%)
MSFT   200.59 (-3.29%)
FB   249.02 (-2.25%)
GOOGL   1,409.39 (-3.45%)
AMZN   2,999.86 (-4.13%)
NVDA   484.95 (-4.07%)
TSLA   380.36 (-10.34%)
BABA   272.95 (-0.85%)
CGC   14.60 (-8.98%)
GE   6.11 (-2.24%)
MU   49.85 (+0.30%)
AMD   74.73 (-3.82%)
T   27.87 (-2.24%)
F   6.64 (-2.06%)
ACB   5.17 (-29.37%)
GILD   63.09 (-0.49%)
NFLX   470.61 (-4.19%)
DIS   123.28 (-3.09%)
BAC   23.26 (-2.84%)
BA   151.18 (-3.58%)
S&P 500   3,236.92 (-2.37%)
DOW   26,763.13 (-1.92%)
QQQ   264.16 (-3.05%)
AAPL   107.12 (-4.19%)
MSFT   200.59 (-3.29%)
FB   249.02 (-2.25%)
GOOGL   1,409.39 (-3.45%)
AMZN   2,999.86 (-4.13%)
NVDA   484.95 (-4.07%)
TSLA   380.36 (-10.34%)
BABA   272.95 (-0.85%)
CGC   14.60 (-8.98%)
GE   6.11 (-2.24%)
MU   49.85 (+0.30%)
AMD   74.73 (-3.82%)
T   27.87 (-2.24%)
F   6.64 (-2.06%)
ACB   5.17 (-29.37%)
GILD   63.09 (-0.49%)
NFLX   470.61 (-4.19%)
DIS   123.28 (-3.09%)
BAC   23.26 (-2.84%)
BA   151.18 (-3.58%)
Log in
NASDAQ:HCM

HUTCHISON CHINA/S Stock Forecast, Price & News

$32.70
-0.75 (-2.24 %)
(As of 09/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$32.67
Now: $32.70
$33.79
50-Day Range
$28.39
MA: $33.16
$34.61
52-Week Range
$14.74
Now: $32.70
$34.90
Volume118,355 shs
Average Volume276,624 shs
Market Capitalization$4.36 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.19
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments. The company discovers and develops therapeutics in oncology and autoimmune diseases, as well as provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, a c-MET inhibitor for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, a inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; and HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma, as well as HMPL-689, a treatment for indolent non-Hodgkin's lymphoma and healthy volunteers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.
Read More
HUTCHISON CHINA/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.97 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HCM
CUSIPN/A
Phone852-2121-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$204.89 million
Book Value$2.35 per share

Profitability

Miscellaneous

Employees714
Market Cap$4.36 billion
Next Earnings DateN/A
OptionableNot Optionable
$32.70
-0.75 (-2.24 %)
(As of 09/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HCM News and Ratings via Email

Sign-up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











HUTCHISON CHINA/S (NASDAQ:HCM) Frequently Asked Questions

How has HUTCHISON CHINA/S's stock been impacted by Coronavirus (COVID-19)?

HUTCHISON CHINA/S's stock was trading at $23.04 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HCM stock has increased by 41.9% and is now trading at $32.70.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of HUTCHISON CHINA/S?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HUTCHISON CHINA/S in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for HUTCHISON CHINA/S
.

What price target have analysts set for HCM?

4 brokers have issued 12 month price targets for HUTCHISON CHINA/S's shares. Their forecasts range from $29.00 to $29.00. On average, they anticipate HUTCHISON CHINA/S's stock price to reach $29.00 in the next year. This suggests that the stock has a possible downside of 11.3%.
View analysts' price targets for HUTCHISON CHINA/S
.

Are investors shorting HUTCHISON CHINA/S?

HUTCHISON CHINA/S saw a increase in short interest in August. As of August 14th, there was short interest totaling 1,330,000 shares, an increase of 31.7% from the July 30th total of 1,010,000 shares. Based on an average trading volume of 314,700 shares, the short-interest ratio is currently 4.2 days.
View HUTCHISON CHINA/S's Short Interest
.

Who are some of HUTCHISON CHINA/S's key competitors?

What other stocks do shareholders of HUTCHISON CHINA/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HUTCHISON CHINA/S investors own include Telford Homes (TEF), AbbVie (ABBV), Exelixis (EXEL), Premier Oil (PMO), Crispr Therapeutics (CRSP), GW Pharmaceuticals PLC- (GWPH), AT&T (T), Johnson & Johnson (JNJ), NVIDIA (NVDA) and Weyerhaeuser (WY).

Who are HUTCHISON CHINA/S's key executives?

HUTCHISON CHINA/S's management team includes the following people:
  • Mr. Chi Keung To B.Sc., M.B.A., BSc, ACGI, MBA, Exec. Chairman (Age 67)
  • Mr. Christian Hogg B.Sc., M.B.A., BSc, MBA, CEO & Exec. Director (Age 53)
  • Mr. Johnny Cheng C.A., BEc, CA, CFO & Exec. Director (Age 52)
  • Dr. Weiguo Su B.Sc., Ph.D., Chief Scientific Officer, Exec. VP & Exec. Director (Age 62)
  • Ms. Edith Shih B.S., M.A., BSE, MA, EdM, Solicitor, FCIS, FCS(PE), Company Sec. & Non-Exec. Director (Age 67)

When did HUTCHISON CHINA/S IPO?

(HCM) raised $100 million in an initial public offering on Thursday, March 17th 2016. The company issued 6,100,000 shares at a price of $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities served as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers.

What is HUTCHISON CHINA/S's stock symbol?

HUTCHISON CHINA/S trades on the NASDAQ under the ticker symbol "HCM."

Who are HUTCHISON CHINA/S's major shareholders?

HUTCHISON CHINA/S's stock is owned by a variety of retail and institutional investors. Top institutional investors include M&G Investment Management Ltd. (2.60%), Zeal Asset Management Ltd (1.12%), Bellevue Group AG (0.71%), Sumitomo Mitsui Trust Holdings Inc. (0.36%), Bank of America Corp DE (0.31%) and FMR LLC (0.19%).

Which institutional investors are selling HUTCHISON CHINA/S stock?

HCM stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, FMR LLC, M&G Investment Management Ltd., Sumitomo Mitsui Trust Holdings Inc., Nuveen Asset Management LLC, Teacher Retirement System of Texas, Tobam, and Vident Investment Advisory LLC.

Which institutional investors are buying HUTCHISON CHINA/S stock?

HCM stock was acquired by a variety of institutional investors in the last quarter, including Zeal Asset Management Ltd, Bellevue Group AG, Bank of America Corp DE, Canada Pension Plan Investment Board, Assenagon Asset Management S.A., Bridgewater Associates LP, Goldman Sachs Group Inc., and Candriam Luxembourg S.C.A..

How do I buy shares of HUTCHISON CHINA/S?

Shares of HCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is HUTCHISON CHINA/S's stock price today?

One share of HCM stock can currently be purchased for approximately $32.70.

How big of a company is HUTCHISON CHINA/S?

HUTCHISON CHINA/S has a market capitalization of $4.36 billion and generates $204.89 million in revenue each year. The company earns $-106,020,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. HUTCHISON CHINA/S employs 714 workers across the globe.

What is HUTCHISON CHINA/S's official website?

The official website for HUTCHISON CHINA/S is www.chi-med.com.

How can I contact HUTCHISON CHINA/S?

HUTCHISON CHINA/S's mailing address is 48TH FLOOR CHEUNG KONG CENTER 2 QUEEN`S ROAD CENTRAL, HONG KONG K3, . The company can be reached via phone at 852-2121-8200 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.